Interview 2013 de Stephane Horel sur les Perturbateurs Endocriniens, Objets de tous les Lobbies

Stéphane Horel est journaliste indépendante spécialisée dans les conflits d’intérêts et les questions d’influence dans le domaine de la santé

Les perturbateurs endocriniens, objets de tous les lobbies
Stéphane Horel est journaliste indépendante et documentariste

Il n’est pas si courant de pouvoir observer en temps réel les manœuvres de lobbying de l’industrie pour influencer l’élaboration d’une politique publique périlleuse pour ses intérêts. La publication, par la Commission européenne, de la définition et des critères concernant les perturbateurs endocriniens (PE) est un cas d’école, car elle aura des conséquences économiques d’importance dans les domaines de la chimie, des pesticides, des biocides, mais aussi des cosmétiques ou de l’eau. La DG Environnement, qui devait se prononcer en décembre prochain, envisage maintenant de lancer une procédure d’évaluation d’impact (économique), qui repoussera de 6 à 8 mois la prise de définition. Il s’agissait d’une des revendications de l’industrie. ”

Lisez Les perturbateurs endocriniens, objets de tous les lobbies,
de Marine Jobert, avec l’interview de Stéphane Horel,
journaliste et documentariste spécialisée sur les conflits d’intérêts
Le journal de l’environnement, 23 septembre 2013

Topamax and Birth Defects: Trial opens in Philadelphia

Janssen’s Topamax Users blame Drug for Birth Defects

Janssen's Topamax Users Blame Drug for Birth Defects
Bloomberg News is the first word in business and finance

Johnson & Johnson’s (JNJ) Janssen Pharmaceuticals failed to inform expectant mothers of risks that its epilepsy drug Topamax could cause birth defects, a lawyer for the mother of a Virginia 6-year-old told a jury. April Czimmer wouldn’t have taken Topamax for more than six months had she known the risks associated with the drug, her attorney Tommy Fibich said in opening statements today in state court in Philadelphia. Czimmer blames the drug for her son’s cleft palate and lip and claims Janssen negligently failed to inform patients about its risks until the U.S. Food and Drug Administration ordered stronger warnings in 2011. ”

Continue reading Janssen’s Topamax Users Blame Drug for Birth Defects, by Sophia Pearson, Bloomberg, 15 Oct 2013

All our posts tagged AEDsTopamaxTopiramateValproate

Le Professeur Michel Tournaire commente l’étude Réseau DES France Distilbène 3 Générations de 2013

Vidéo par Réseau DES FRANCE DISTILBENE, 05 Nov 2013

Pour la première fois en France, une étude a été lancée pour permettre de déterminer les risques de cancer du sein chez les filles DES soumises in-utero à l’hormone de synthèse Distilbène®, ce médicament prescrit aux femmes enceintes jusqu’à la fin des années 70 et sensé prevenir les fausses couches. Le Professeur Michel Tournaire commente l’étude Distilbène trois générations menée en 2013 par l’association Réseau D.E.S. France.

  • Vidéo par Réseau DES FRANCE DISTILBENE, 05 Nov 2013
    • Pourquoi une nouvelle recherche sur le DES est-elle nécessaire en France?
    • Quelles sont les conséquences déjà connues pour ces filles DES?
    • Quelles sont les nouvelles inquiétudes pour les filles DES?
    • Quelles sont les buts de cette étude?
    • Comment assurer le succès de cette étude?
Le Distilbène DES, en savoir plus

La Fabrique du Mensonge, Industriels manipulant la Science nous mettant en Danger

Par Stéphane Foucart, journaliste scientifique au journal Le Monde

La Fabrique du Mensonge sur Flickr
Stéphane Foucart, journaliste scientifique au Monde, accessoirement auteur de livres inflammatoires

Un pan entier de l’activité des grandes entreprises consiste aujourd’hui à manipuler la science. Confrontés aux faits, les industriels utilisent le discours scientifique comme un instrument de propagande pour instiller le doute. Les fabricants de tabac sont les premiers à avoir recruté des faux experts, fait publier des études biaisées, organisé des fausses conférences scientifiques et corrompu des sociétés savantes afin de convaincre que le tabac n’était peut-être pas responsable du cancer du poumon. Les mêmes procédés ont été remis au goût du jour pour dédouaner l’amiante de ses méfaits, pour relativiser ou nier le réchauffement climatique, pour faire du déclin des abeilles un «mystère» sans lien avec les nouvelles générations d’insecticides. Ils sont également à l’œuvre dans l’affaire du bisphénol A, l’un des plus graves scandales sanitaires de ces dernières décennies. Quant au «débat» sur les OGM, cela fait bien longtemps qu’il n’a plus rien à voir avec la science. Les intérêts en jeu sont trop colossaux pour laisser les chercheurs s’exprimer librement… Au-delà de tout militantisme, La Fabrique du mensonge décortique les mécanismes de ces manœuvres et montre comment abîmer la science et détruire le savoir met nos vies en danger.

KwaliteitsCriteria bij Screenings-Protocol van DES-dochters

DES Centrum NL behartigen de belangen van alle generaties die zijn blootgesteld aan DES, ofwel diethylstilbestrol

In 2012 heeft het DES Centrum het screeningsprotocol DES-dochters vernieuwd op basis van de meest recente kennis, een belangrijk startpunt voor goede zorg aan DES-dochters. Goede zorg is echter meer dan alleen medisch goede zorg. Daarom is aan dit screeningsprotocol een set van kwaliteitscriteria toegevoegd. Deze criteria zijn gebaseerd op de wensen en behoeften van DES-dochters en verkregen uit een enquête en twee focusgroepen die onder en met de DES-dochters gehouden zijn.

Kwaliteitscriteria bij screeningsprotocol DES-dochters
DES Centrum NL behartigen de belangen van alle generaties die zijn blootgesteld aan DES, ofwel diethylstilbestrol. Ze zijn hét kenniscentrum op dit gebied en zijn online!

PDF Dossiers om te lezen, downloaden, printen:

Onze gerelateerde berichten:

Anne Levadou, Présidente du Réseau DES France, présente leur étude Distilbène 3 Générations de 2013

Déterminer les risques transgénérationnels du Distilbène

Pour la première fois en France, une étude a été lancée pour permettre de déterminer les risques de cancer du sein chez les filles DES  soumises in-utero à l’hormone de synthèse Distilbène®médicament prescrit aux femmes enceintes jusqu’à la fin des années 70 et sensé prevenir les fausses couches. Anne Levadou, Présidente de l’association Réseau D.E.S. France présente leur étude Distilbène trois générations menée en 2013.

Le Distilbène DES, en savoir plus

Clinical Trials: Half of all Trials are missing Results in 2013

Clinical trial registration, reporting, publication and FDAAA compliance: unacceptably low

Linking ClinicalTrials.gov and PubMed to Track Results of Interventional Human Clinical Trials
PLOS ONE is an international, peer-reviewed, open-access, online publication

In an effort to understand how results of human clinical trials are made public, researchers analyzed 8907 clinical trials completed in 2006-2009 and registered at ClinicalTrials.gov, the world’s largest clinical trial registry.

Only 47% of trials analyzed in their large sample provided linked publications or basic results. Despite availability of several information channels, trial record managers do not sufficiently meet the mandate to inform the public about results of clinical trials either via a linked result publication or basic results submission, although there is a temporal trend showing an increasing rate of submission of basic results.

Read Linking ClinicalTrials.gov and PubMed to Track Results of Interventional Human Clinical Trials, PlosOne, Oct 2013

Related Posts:

Exposure to Synthetic Estrogens at different Times during the Life and their Side Effects on Health

Synthetic Estrogens exposures induce epigenetic modifications for multiple generations

2013 Study Abstract:

Exposures to Synthetic Estrogens at Different Times During the Life, and Their Effect on Breast Cancer Risk
Synthetic Estrogens exposures induce epigenetic modifications for multiple generations

Women are using estrogens for many purposes, such as to prevent pregnancy or miscarriage, or to treat menopausal symptoms. Estrogens also have been used to treat breast cancer which seems puzzling, since there is convincing evidence to support a link between high lifetime estrogen exposure and increased breast cancer risk. In this review, we discuss the findings that maternal exposure to the synthetic estrogen diethylstilbestrol during pregnancy increases breast cancer risk in both exposed mothers and their daughters. In addition, we review data regarding the use of estrogens in oral contraceptives and as postmenopausal hormone therapy and discuss the opposing effects on breast cancer risk based upon timing of exposure. We place particular emphasis on studies investigating how maternal estrogenic exposures during pregnancy increase breast cancer risk among daughters. New data suggest that these exposures induce epigenetic modifications in the mammary gland and germ cells, thereby causing an inheritable increase in breast cancer risk for multiple generations.

2013 Study Conclusion:

Women use estrogens for many purposes. During pregnancy, synthetic strogen DES was used to prevent miscarriage and promote healthy pregnancy, although it turned out to cause the opposite. During the reproductive years when a woman’s own estrogen levels are high, women use synthetic estrogens as contraceptives. Since estrogens play an important role in normal physiological functions in women, some menopausal and postmenopausal women use estrogen supplementation to regain the benefits of natural estrogens.

The effects of estrogens on breast cancer risk differ depending upon when during a woman’s life time they are used. Maternal exposure to DES during pregnancy increases breast cancer risk in mothers and their daughters. The adverse effects of synthetic estrogen exposure during pregnancy may not be limited to mothers and their daughters. Our preclinical study in rodents showed that maternal exposure to EE2 increases breast cancer risk in daughters, granddaughters, and great granddaughters. The first generation of OCs increased breast cancer risk at the time women were taking them, but the increase in risk was not permanent. The current, third generation contraceptives do not increase breast cancer risk. Menopausal and postmenopausal HT, if it contains both estrogens and progestin, increases a woman’s breast cancer risk, and recent data suggest that tumors developing during therapy are more aggressive than those in women not using HT. Estrogen-only HT does not increase breast cancer risk, and might even reduce it. However, due to other adverse effects of estrogen-only HT, it is not recommended beyond using it to control the most severe menopausal symptoms.

We are beginning to understand how the increase in breast cancer risk following in utero exposures to synthetic estrogens occurs. It most likely involves long-term epigenetic changes in genes that are important in determining the risk for breast cancer development, such as tumor suppressor genes, PcTGs and oncogenes. Briefly, an exposure to synthetic estrogens during the fetal period induces modifications in the epigenetic reprogramming of the genome, leading to changes in mammary gland morphology, and gene and protein expression. Some of these changes are transient, such as an increase in the number of TEBs in rodents, and some persist, such as an altered gene and protein expression involving tumor suppressor genes and oncogenes. Together, epigenetically induced modifications in the mammary gland morphology and gene expression increase the likelihood that environmental carcinogens and radiation induce malignant transformation, and evetually breast cancer. The next challenge is to determine whether the increase in risk can be reversed by reversing epigenetic changes that occur as a consequence of early life exposure to synthetic estrogens.

Additional Information : Exposures to Synthetic Estrogens at Different Times During the Life, and Their Effect on Breast Cancer Risk, Springer, Journal of Mammary Gland Biology and Neoplasia, Volume 18, Issue 1, March 2013, Special Issue: Environmental Risk Factors. Full text on NCBI PMC3635108.

More DES DiEthylStilbestrol Resources

Prenatal DES Exposure in Relation to Breast Size

Greater mammary gland mass and increased risk of breast cancer for the DES-exposed

2013 Study Abstract:

Prenatal DES exposure in relation to breast size
DES exposure may result in greater mammary gland mass and increase the risk of breast cancer

PURPOSE:
Prenatal DES exposure has been associated with increased risk of breast cancer, but the mechanisms are unknown. Larger bra cup size has also been associated with increased breast cancer risk, although not consistently. We investigated the relation of prenatal DES exposure to mammary gland mass, as estimated by bra cup size.

METHODS:
In 2006, 3,222 DES-exposed and 1,463 unexposed women reported their bra cup size, band size (chest circumference), and weight at age 20. Prevalence ratios (PR) were calculated for DES exposure in relation to large bra cup size, with control for year of birth and study cohort. Primary analyses were carried out among women who reported a chest circumference of no more than 32 inches because their cup size would be less influenced by fat mass.

RESULTS:
Within this group, DES-exposed women had an estimated 45 % increased prevalence (95 % CI 0.97-2.18) of large cup size (C or greater) relative to unexposed women. The PR was further increased among women in this group who had a body mass index of < 21 at age 20: PR = 1.83 (95 % CI 1.11-3.00). The PR for high-dose DES exposure relative to no exposure was 1.67, 95 % CI 1.02-2.73, whereas there was no association of bra cup size with low-dose exposure.

CONCLUSIONS:
These results provide support for the hypothesis that in utero DES exposure may result in greater mammary gland mass. Taken together with previous research on bra size and breast cancer risk, these findings suggest a mechanism for a possible association of in utero DES exposure with increased risk of breast cancer.

Sources:

  • Sources: Prenatal DES Exposure in Relation to Breast Size, NCBI, Dr R Hoover, PMID: 23775027, 2013 Sep;24(9):1757-61. doi: 10.1007/s10552-013-0248-3. Epub 2013 Jun 18. Full text link.
More DES DiEthylStilbestrol Resources

Hot Flash Havoc Trailer

Entertaining, at times Laugh-out-loud funny take on Menopause

Watch the trailer of Hot Flash Havoc, a film of “Menopausal Proportions”…